Cargando…

Peretinoin after curative therapy of hepatitis C-related hepatocellular carcinoma: a randomized double-blind placebo-controlled study

BACKGROUND: Effective prophylactic therapies have not been established for hepatocellular carcinoma recurrence. Peretinoin represents one novel option for patients with hepatitis C virus-related hepatocellular carcinoma (HCV-HCC), and it was tested in a multicenter, randomized, double-blind, placebo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Okita, Kiwamu, Izumi, Namiki, Matsui, Osamu, Tanaka, Katsuaki, Kaneko, Shuichi, Moriwaki, Hisataka, Ikeda, Kenji, Osaki, Yukio, Numata, Kazushi, Nakachi, Kohei, Kokudo, Norihiro, Imanaka, Kazuho, Nishiguchi, Shuhei, Okusaka, Takuji, Nishigaki, Yoichi, Shiomi, Susumu, Kudo, Masatoshi, Ido, Kenichi, Karino, Yoshiyasu, Hayashi, Norio, Ohashi, Yasuo, Makuuchi, Masatoshi, Kumada, Hiromitsu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Japan 2014
Materias:	Original Article—Liver, Pancreas, and Biliary Tract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4318984/ https://www.ncbi.nlm.nih.gov/pubmed/24728665 http://dx.doi.org/10.1007/s00535-014-0956-9

Ejemplares similares

Survey of survival among patients with hepatitis C virus-related hepatocellular carcinoma treated with peretinoin, an acyclic retinoid, after the completion of a randomized, placebo-controlled trial
por: Okita, Kiwamu, et al.
Publicado: (2014)

Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON
por: Kudo, Masatoshi, et al.
Publicado: (2016)

REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
por: Yamashita, Tatsuya, et al.
Publicado: (2019)

Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma
por: Ikeda, Kenji, et al.
Publicado: (2016)

Mass Spectrometry-Based (GeLC-MS/MS) Comparative Proteomic Analysis of Endoscopically (ePFT) Collected Pancreatic and Gastroduodenal Fluids
por: Paulo, Joao A, et al.
Publicado: (2012)

Dramatic Survival Benefit Related to R0 Resection of Pancreatic Adenocarcinoma in Patients With Tumor ≤25 mm in Size and ≤1 Involved Lymph Nodes
por: Tummala, Pavan, et al.
Publicado: (2013)

A Pilot Study to Develop a Diagnostic Test for Pancreatic Ductal Adenocarcinoma Based on Differential Expression of Select miRNA in Plasma and Bile
por: Cote, Gregory A, et al.
Publicado: (2014)

Inhibition of hepatocellular carcinoma by PegIFNα-2a in patients with chronic hepatitis C: a nationwide multicenter cooperative study
por: Izumi, Namiki, et al.
Publicado: (2012)

Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multicenter cohort study
por: Tateishi, Ryosuke, et al.
Publicado: (2014)

Transarterial chemoembolization with miriplatin vs. epirubicin for unresectable hepatocellular carcinoma: a phase III randomized trial
por: Ikeda, Masafumi, et al.
Publicado: (2017)

A randomized controlled trial of lusutrombopag in Japanese patients with chronic liver disease undergoing radiofrequency ablation
por: Tateishi, Ryosuke, et al.
Publicado: (2018)

The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II/III study
por: Kumada, Hiromitsu, et al.
Publicado: (2016)

Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT
por: Okusaka, Takuji, et al.
Publicado: (2021)

Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan
por: Kobayashi, Masahiro, et al.
Publicado: (2019)

Streptozocin chemotherapy for advanced/metastatic well-differentiated neuroendocrine tumors: an analysis of a multi-center survey in Japan
por: Aoki, Taku, et al.
Publicado: (2014)

Systemic inflammation as fuel for acute liver injury in COVID-19
por: Effenberger, Maria, et al.
Publicado: (2021)

Liver fibrosis in patients with metabolic associated fatty liver disease is a risk factor for adverse outcomes in COVID-19
por: Campos-Murguía, Alejandro, et al.
Publicado: (2021)

Hepatocellular liver injury in hospitalized patients affected by COVID-19: Presence of different risk factors at different time points
por: Leo, M., et al.
Publicado: (2022)

Clinical update on risks and efficacy of anti-SARS-CoV-2 vaccines in patients with autoimmune hepatitis and summary of reports on post-vaccination liver injury
por: Lleo, Ana, et al.
Publicado: (2022)

Chronic liver disease-related mortality in diabetes before and during the COVID-19 in the United States
por: Kim, Donghee, et al.
Publicado: (2023)

Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study
por: Iavarone, Massimo, et al.
Publicado: (2023)

COVID-19 vaccination among cirrhotics in Italy: High coverage and effectiveness of 3 doses versus 2 in preventing breakthrough infection and hospitalization
por: Stroffolini, Tommaso, et al.
Publicado: (2023)

Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis
por: Chayama, Kazuaki, et al.
Publicado: (2017)

Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study
por: Kaneko, Shuichi, et al.
Publicado: (2016)

Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan
por: Sakaida, Isao, et al.
Publicado: (2015)

Relevance of the Core 70 and IL-28B polymorphism and response-guided therapy of peginterferon alfa-2a ± ribavirin for chronic hepatitis C of Genotype 1b: a multicenter randomized trial, ReGIT-J study
por: Nishiguchi, Shuhei, et al.
Publicado: (2013)

Impact of early cholecystectomy on the readmission rate in patients with acute gallstone cholangitis: a retrospective single-centre study
por: Hoilat, Gilles Jadd, et al.
Publicado: (2021)

Interventional treatment of biliodigestive anastomosis leaks with a modified percutaneous transhepatic cholangiodrainage
por: Lopez Benitez, Ruben, et al.
Publicado: (2022)

Factors predicting 30-day mortality after ERCP in patients with inoperable malignant hilar biliary obstruction: a single tertiary referral centre experience and systematic review
por: On, Wei, et al.
Publicado: (2022)

Post-transplant biliary complications: advances in pathophysiology, diagnosis, and treatment
por: Fasullo, Matthew, et al.
Publicado: (2022)

Cost-effectiveness analysis of antibiotic prophylaxis versus no antibiotic prophylaxis for acute cholecystectomy
por: Satheeskaran, Maya, et al.
Publicado: (2023)

Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: a phase 2 multicenter study
por: Kudo, Masatoshi, et al.
Publicado: (2021)

Ramucirumab after prior sorafenib in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: Japanese subgroup analysis of the REACH-2 trial
por: Kudo, Masatoshi, et al.
Publicado: (2020)

The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry
por: Satake, Tomoyuki, et al.
Publicado: (2022)

Vaniprevir plus peginterferon alfa-2a and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase II study
por: Hayashi, Norio, et al.
Publicado: (2014)

Incidence and risk factors for venous thromboembolism in the Cancer-VTE Registry pancreatic cancer subcohort
por: Okusaka, Takuji, et al.
Publicado: (2023)

Efficacy and safety of eltrombopag in Japanese patients with chronic liver disease and thrombocytopenia: a randomized, open-label, phase II study
por: Kawaguchi, Takumi, et al.
Publicado: (2012)

Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma
por: Arizumi, Tadaaki, et al.
Publicado: (2014)

Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-naive Japanese patients with hepatitis C virus genotype 1 infection: a randomized phase III study
por: Hayashi, Norio, et al.
Publicado: (2015)

High-sensitivity Lens culinaris agglutinin-reactive alpha-fetoprotein assay predicts early detection of hepatocellular carcinoma
por: Kumada, Takashi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_cvh3v0cb76jqkmdle6jn6c8jhu